ArticleDrugs - real world outcomes2023

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer.

Toshiki Masuishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.